New drugs and strategies for management of clostridium difficile colitis

Journal of Intensive Care Medicine

Volumn 29, Issue 4, 2014, Pages 190-199

  Higa, J T ^a   Kelly, C P ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clostridium difficile; colitis; critical care; drugs; strategies; treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; BACITRACIN; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; FIDAXOMICIN; IMMUNOGLOBULIN; MACROLIDE; METRONIDAZOLE; PENICILLIN DERIVATIVE; PROBIOTIC AGENT; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAXIMIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CRITICALLY ILL PATIENT; DISEASE SEVERITY; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; CLOSTRIDIUM INFECTIONS; COLITIS; CROSS INFECTION; DIARRHEA; INTENSIVE CARE; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS; CRITICAL CARE; CROSS INFECTION; DIARRHEA; HUMANS; IMMUNIZATION; PROBIOTICS; RECURRENCE; RISK FACTORS;

EID: 84904962182     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066613475426     Document Type: Review

References (69)

1. Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am. 2009 ; 23 (3). 727-743
2. Hall IC, Duffett ND. The identification of von Hibler's "Bacillus VI" as Bacillus carnis (Klein). J Bacteriol. 1935 ; 29 (3). 269-291
3. Tedesco FJ, Stanley RJ, Alpers DH. Diagnostic features of clindamycin-associated pseudomembranous colitis. N Engl J Med. 1974 ; 290 (15). 841-843
4. Kachrimanidou M, Malisiovas N. Clostridium difficile infection: a comprehensive review. Crit Rev Microbiol. 2011 ; 37 (3). 178-187
5. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006 ; 12 (3). 409-415
6. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med. 2008 ; 359 (18). 1932-1940
7. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 ; 353 (23). 2442-2449 (Pubitemid 41770165)
8. Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med. 2006 ; 73 (2). 187-197
9. Bartlett JG. Clostridium difficile: progress and challenges. Ann N Y Acad Sci. 2010 ; 1213: 62-69
10. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005 ; 353 (23). 2433-2441 (Pubitemid 41770164)
11. Verdoorn BP, Orenstein R, Rosenblatt JE, et al. High prevalence of tcdC deletion-carrying Clostridium difficile and lack of association with disease severity. Diagn Microbiol Infect Dis. 2010 ; 66 (1). 24-28
12. Cloud J, Noddin L, Pressman A, Hu M, Kelly C.. Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin Gastroenterol Hepatol. 2009 ; 7 (8). 868-873
13. Kelly CP, LaMont JT. Antibiotic-associated diarrhea, Pseudomembranous Enterocolitis, and Clostridium difficile-associated diarrhea and colitis. Sleisenger and Fordtran's Gastrointestinal and Liver Disease - 2 Volume Set: Pathophysiology, Diagnosis, Management. 2010 ; Vol 2: 1889-1903
14. Bouza E, Burrillo A, Munoz P. Antimicrobial therapy of Clostridium difficile-associated diarrhea. Med Clin N Am. 2006 ; 90: 1143
15. Hickson M. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol. 2011 ; 4 (3). 185-197
16. Bobo LD, Dubberke ER, Kollef M. Clostridium difficile in the ICU: the struggle continues. Chest. 2011 ; 140 (6). 1643-1653
17. Unger JA, Whimbey E, Gravett MG, Eschenbach DA.. The emergence of Clostridium difficile infection among peripartum women: a case-control study of a C. difficile outbreak on an obstetrical service. Infect Dis Obstet Gynecol. 2011 ;: 267249
18. Gerding DN, Muto CA, Owens RC. Measures to control and prevent Clostridium difficile infection. Clin Infect dis. 2008 ; 46 (suppl 1). S43 - S49
19. Bliss DZ, Johnson S, Savik K, Clabots CR, Willard K, Gerding DN. Acquisition of clostridium difficile and clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann intern Med. 1998 ; 129 (12). 1012-1019 (Pubitemid 29005824)
20. Iizuka M, Itou H, Konno S, et al. Elemental diet modulates the growth of clostridium difficile in the gut flora. Aliment Pharmacol Ther. 2004 ; 20 (suppl 1). 151-157 (Pubitemid 39120287)
21. O'Keefe SJ. Tube feeding, the microbiota, and clostridium difficile infection. World J Gastroenterol. 2010 ; 16 (2). 139-142
22. O'Keefe SJ, Lee RB, Anderson FP, et al. Physiological effects of enteral and parenteral feeding on pancreaticobiliary secretion in humans. Am J Physiol Gastrointest Liver Physiol. 2003 ; 284 (1). G27 - G36
23. Kelly CP. A 76-year-old man with recurrent clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA. 2009 ; 301 (9). 954-962
24. Kelly CP, Pothoulakis C, Lamont JT. Clostridium difficile colitis. N Engl J Med. 1994 ; 330 (4). 259-260
25. Kirkpatrick ID, Greenberg HM. Evaluating the CT diagnosis of clostridium difficile colitis: should CT guide therapy?. AJR Am J Roentgenol. 2001 ; 176 (3). 635-639 (Pubitemid 32181955)
26. Bobo LD, Dubberke ER. Recognition and prevention of hospital-associated enteric infections in the intensive care unit. Crit Care Med. 2010 ; 38 (suppl 8). S324 - S334
27. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the Society For Healthcare Epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010 ; 31 (5). 431-455
28. Chapin KC, Dickenson RA, Wu F, Andrea SB. Comparison of five assays for detection of clostridium difficile toxin. J Mol Diagn. 2011 ; 13 (4). 395-400
29. Deshpande A, Pasupuleti V, Rolston DD, et al. Diagnostic accuracy of real-time polymerase chain reaction in detection of clostridium difficile in the stool samples of patients with suspected clostridium difficile infection: a meta-analysis. Clin Infect Dis. 2011 ; 53 (7). e81 - e90
30. Sheth SG, LaMont JT. Gastrointestinal problems in the chronically critically ill patient. Clin Chest Med. 2001 ; 22 (1). 135-147 (Pubitemid 32290600)
31. Gerding DN, Muto CA, Owens RC. Treatment of clostridium difficile infection. Clin Infect Dis. 2008 ; 46 (suppl 1). S32 - S42
32. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007 ; 45 (3). 302-307 (Pubitemid 47101025)
33. Zilberberg MD, Shorr AF, Micek ST, Doherty JA, Kollef MH. Clostridium difficile-associated disease and mortality among the elderly critically ill. Crit Care Med. 2009 ; 37 (9). 2583-2589
34. Wilcox MH, Howe R. Diarrhoea caused by clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother. 1995 ; 36 (4). 673-679
35. Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol. 2008 ; 29 (suppl 1). S81 - S92
36. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for clostridium-difficile-associated diarrhoea and colitis. Lancet. 1983 ; 2 (8358). 1043-1046 (Pubitemid 14235361)
37. Aslam S, Musher DM. An update on diagnosis, treatment, and prevention of clostridium difficile-associated disease. Gastroenterol Clin North Am. 2006 ; 35 (2). 315-335 (Pubitemid 44118670)
38. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of clostridium difficile-associated diarrhea. Clin Infect Dis. 1996 ; 22 (5). 813-818 (Pubitemid 26255600)
39. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis. 2008 ; 47 (1). 56-62 (Pubitemid 351920588)
40. Bartlett JG. New antimicrobial agents for patients with clostridium difficile infections. Curr Infect Dis Rep. 2009 ; 11 (1). 21-28
41. Shen EP, Surawicz CM. Current treatment options for severe clostridium difficile-associated disease. Gastroenterol Hepatol. 2008 ; 4 (2). 134-139 (Pubitemid 351428035)
42. Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007 ; 245 (2). 267-272 (Pubitemid 46148486)
43. Gash K, Brown E, Pullyblank A. Emergency subtotal colectomy for fulminant clostridium difficile colitis - is a surgical solution considered for all patients?. Ann R Coll Surg Engl. 2010 ; 92 (1). 56-60
44. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011 ; 53 (5). 440-447
45. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent clostridium difficile diarrhoea. Lancet. 2001 ; 357 (9251). 189-193 (Pubitemid 32108091)
46. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS.. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated clostridium difficile associated disease. Ann Surg. 2011 ; 254 (3). 423-427
47. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent clostridium difficile disease. Am J Gastroenterol. 2002 ; 97 (7). 1769-1775 (Pubitemid 34761404)
48. Maroo S, Lamont JT. Recurrent clostridium difficile. Gastroenterology. 2006 ; 130 (4). 1311-1316
49. Kelly CP, Kyne L. The host immune response to clostridium difficile. J Med Microbiol. 2011 ; 60 (Pt 8). 1070-1079
50. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for clostridium difficile infection. N Engl J Med. 2011 ; 364 (5). 422-431
51. Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with clostridium difficile infection. J Antimicrob Chemother. 2011 ; 66 (12). 2850-2855
52. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short- and long-term attributable costs of clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008 ; 46 (4). 497-504 (Pubitemid 351263485)
53. Gordin FM, Schultz ME, Huber RA, Gill JA. Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. Infect Control Hosp Epidemiol. 2005 ; 26 (7). 650-653 (Pubitemid 41073407)
54. Abbett SK, Yokoe DS, Lipsitz SR, et al. Proposed checklist of hospital interventions to decrease the incidence of healthcare-associated clostridium difficile infection. Infect Control Hosp Epidemiol. 2009 ; 30 (11). 1062-1069
55. Al-Obaydi W, Smith CD, Foguet P. Changing prophylactic antibiotic protocol for reducing clostridium difficile-associated diarrhoeal infections. J Orthop Surg (Hong Kong). 2010 ; 18 (3). 320-323
56. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of clostridium difficile-infected patients than does vancomycin. Microbiology. 2010 ; 156 (Pt 11). 3354-3359
57. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007 ; 44 (6). 846-848 (Pubitemid 46365312)
58. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis. 2009 ; 48 (4). e41 - e46
59. Gerding DN, Johnson S. Management of clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis. 2010 ; 51 (11). 1306-1313
60. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory clostridium difficile infection. Clin Infect Dis. 2009 ; 48 (12). 1732-1735
61. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000 ; 342 (6). 390-397 (Pubitemid 30084537)
62. Lee BY, Popovich MJ, Tian Y, et al. The potential value of clostridium difficile vaccine: an economic computer simulation model. Vaccine. 2010 ; 28 (32). 5245-5253
63. Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of clostridium difficile infection: a review. Dig Dis Sci. 2011 ; 56 (1). 19-26
64. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against clostridium difficile toxins. N Engl J Med. 2010 ; 362 (3). 197-205
65. Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun. 2003 ; 71 (3). 1608-1610 (Pubitemid 36254357)
66. Na X, Kelly C.. Probiotics in clostridium difficile infection. J Clin Gastroenterol. 2011 ; 45 (suppl). S154 - S158
67. Pillai A, Nelson R.. Probiotics for treatment of clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008 ; (1). CD004611
68. Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol. 2010 ; 44 (8). 562-566
69. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010 ; 44 (5). 354-360